These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 12200368)

  • 1. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
    Bougie DW; Wilker PR; Wuitschick ED; Curtis BR; Malik M; Levine S; Lind RN; Pereira J; Aster RH
    Blood; 2002 Sep; 100(6):2071-6. PubMed ID: 12200368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
    Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH;
    J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors.
    Christopoulos CG
    Blood; 2003 Feb; 101(4):1655; author reply 1655. PubMed ID: 12560245
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
    Abrams CS; Cines DB
    Curr Hematol Rep; 2004 Mar; 3(2):143-7. PubMed ID: 14965491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.
    Bougie DW; Rasmussen M; Zhu J; Aster RH
    Blood; 2012 Jun; 119(26):6317-25. PubMed ID: 22490676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
    Tcheng JE
    Am Heart J; 2000 Feb; 139(2 Pt 2):S38-45. PubMed ID: 10650315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.
    Greinacher A; Fuerll B; Zinke H; Müllejans B; Krüger W; Michetti N; Motz W; Schwertz H
    Blood; 2009 Aug; 114(6):1250-3. PubMed ID: 19429867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
    J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptifibatide-induced acute profound thrombocytopenia: a case report.
    Graidis C; Golias C; Dimitriadis D; Dimitriadis G; Bitsis T; Dimitrelos I; Tsiakou A; Charalabopoulos K
    BMC Res Notes; 2014 Feb; 7():107. PubMed ID: 24564943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.
    Puri A; Bansal A; Narain VS; Sethi R; Dwivedi SK; Puri VK; Saran RK
    Indian Heart J; 2013; 65(2):152-7. PubMed ID: 23647894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.
    Aster RH
    Chest; 2005 Feb; 127(2 Suppl):53S-59S. PubMed ID: 15706031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GPIIb-IIIa inhibitors].
    Nurden P
    Transfus Clin Biol; 2001 Apr; 8(2):114-22. PubMed ID: 11386043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 17. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation.
    Corominas N; Perez J; Ortiz J; Ferrer E; Ribas J; Sanz G
    Pharm World Sci; 2004 Feb; 26(1):38-43. PubMed ID: 15018258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].
    Agnelli D; Ottani F
    G Ital Cardiol (Rome); 2008 Feb; 9(2):137-43. PubMed ID: 18383777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.